Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals — Q4 2025 Earnings Presentation
43 slides from Day One Biopharmaceuticals's earnings presentation, February 2026
Slide 1: Day One Biopharmaceuticals
Day One Biopharmaceuticals Targeted therapies for people of all ages February 2026
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some
Slide 3: Inspired by the urgent needs of children
Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life- threatening diseases 3
Slide 4: Bringing life-changing medicines to patients sooner
Bringing life-changing medicines to patients sooner Who we are • Commercial-stage biopharmaceutical company • Our goal is to develop and provide access to targeted new medicines to patients of all ages as rapidly as possible • Focused on advancing first- or best-in-class medicines for childhood and
Slide 5: Positioned for accelerating growth in 2026
Positioned for accelerating growth in 2026 We build long-term value by boldly advancing care for patients of all ages with high unmet needs 2026+ Growth • Solidify OJEMDA as 2L SOC in r/r pLGG 2025 Execution • 1L OJEMDA doubles pLGG ü 6 consecutive quarters of market opportunity double-digit growth
Slide 6: Our pipeline
Our pipeline Phase 1 Phase 1 Product / Product Therapeutic Phase 3/ Recent & Anticipated Dose Dose Phase 2 Approved Candidate Area Registrational Milestones Escalation Expansion OJEMDA1 3-year follow-up data publication (Tovorafenib) BRAF-altered submission FIREFLY-1 (pivotal Phase 2)2 Q1 2026 Type
Slide 7: Well positioned for sustained growth and value generation
Well positioned for sustained growth and value generation OJEMDA OJEMDA expansion Emi-Le $1B+ U.S. in R/R pLGG in 1L pLGG in ACC revenue opportunity in >$400M + >$500M + >$300M 3 high Durable, growing Expands earlier into Third, high-value unmet need revenue foundation treatment paradigm program ind
Slide 8: OJEMDA
OJEMDA Relapsed or refractory BRAF-altered pLGG Nora Living with pLGG 8
Slide 9: Pediatric low-grade glioma: The most common type of brain tumor in children
Pediatric low-grade glioma: The most common type of brain tumor in children A serious and life-threatening disease • For the majority of patients with pLGG in the relapsed setting, there is no standard of care, and until recently, no approved therapies pLGGs are chronic and • Up to 75% of pLGGs have
Slide 10: Overview U.S. prescribing information for OJEMDA
Overview U.S. prescribing information for OJEMDA Available in tablet formulation and pediatric- friendly powder for oral suspension Indication OJEMDA is indicated for the treatment of pediatric patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF
Slide 11: OJEMDA is redefining the treatment paradigm in relapsed or refractory pLGG
OJEMDA is redefining the treatment paradigm in relapsed or refractory pLGG • Clinical data reinforce OJEMDA’s role in the r/r pLGG treatment paradigm • Three-year follow-up data (Society for Neuro-Oncology 2025) reinforce durability of OJEMDA and align with how physicians manage pLGG Growing long-te
Slide 12: OJEMDA's durable clinical benefit supports its adoption as 2L SOC
OJEMDA’s durable clinical benefit supports its adoption as 2L SOC OJEMDA Clinical Profile FIREFLY-1: 3-Year Data1 • Durable responses, retreatment • Median duration of response 19.4 months feasibility1 • Median time to next treatment 42.6 months • Data consistent with chronic use in • 77% of patient
Slide 13: Foundational U.S. opportunity for OJEMDA in both relapsed and frontline pLGG
Foundational U.S. opportunity for OJEMDA in both relapsed and frontline pLGG Incident Therapeutic Build for New Illustrative pLGG Patient Flow§ pLGG Patients to be Treated in Prevalence of Systemically-Treated Patients Under 25 Years ~26,000 Frontline Setting Frontline (1L) Relapsed / Refractory (2L
Slide 14: OJEMDA has meaningful runway for increased utilization in the 2L+ pLGG market
OJEMDA has meaningful runway for increased utilization in the 2L+ pLGG market Meaningful Runway for OJEMDA Increased Utilization ~1,100 unique r/r pLGG treatment decisions annually 2,3 • Current penetration reflects only a portion of the addressable r/r market, indicating substantial headroom for OJ
Slide 15: Commercial execution and clinical impact driving strong revenue growth
Commercial execution and clinical impact driving strong revenue growth OJEMDA Net Product Revenue OJEMDA Prescriptions (TRx) $155.4M (+172%) in 2025 1 4,635 (+181%)1 in 2025 $52.8 1,394 (+37%)2 (+11%)2 ~36% ~34% 1,256 CQGR $38.5 CQGR 1,062 $33.6 923 $30.5 799 $29.0 610 $20.1 $8.2 238 Q2 Q3 Q4 Q1 Q2
Slide 16: Commercial execution driving strong 2026 OJEMDA outlook
Commercial execution driving strong 2026 OJEMDA outlook OJEMDA U.S. Net Product Revenue Named Patient Program Net Revenue Transitioned to Ipsen >50% growth at the midpoint $225-$250M FF-1 3-Year Follow-Up OJEMDA 2026 Expected Net Product Revenue Data Fuels Expected 2026 Growth: $155.4M • Solidifying
Slide 17: Our strategy: focused execution to solidify OJEMDA as 2L standard of care
Our strategy: focused execution to solidify OJEMDA as 2L standard of care Drive New Patient Starts Increase depth of prescribing through continued evidence generation that reinforces how OJEMDA’s clinical profile and benefits align with attributes physicians prioritize when treating pLGG patients* O
Slide 18: OJEMDA IP summary and regulatory designations
OJEMDA IP Intellectual Property summary and • Composition of matter patent of tovorafenib provides protection in the U.S. out to mid-2036 (with patent term extension)1 regulatory • Patent portfolio covers formulations, manufacturing methods, and designations uses of tovorafenib, with issued and pend
Slide 19: 3-year follow-up data from the FIREFLY-1 trial studying OJEMDA
3-year follow- up data from the FIREFLY-1 trial studying OJEMDA Phase 2 FIREFLY-1 Trial 19
Slide 20: After 26 OJEMDA cycles, patients could enter an observation period
After 26 OJEMDA cycles, patients could enter an observation period* Updated 3-year analysis Time to next treatment, n=76† Subsequent anticancer therapy Treatment-free interval, n=39‡ or death OJEMDA Arm 1, n=77 Observation period Day 1 26 cycles* (~24 months) Received 26 cycles, (no anticancer thera
Slide 21: Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO
Deep, durable responses with OJEMDA evaluated by IRC-assessed RAPNO Updated 3-year analysis 3-year Exposure Arm 1 (n=76)* Completed ≥26 cycles of treatment, n (%) 44/76 (58) Response (IRC) ORR,† n (%) 40 (53) Best Overall Response, n (%) CR 0 PR 30 (39) MR 10 (13) SD‡ 22 (29) PD 13 (17) NE 1 (1) Med
Slide 22: Many patients continued OJEMDA beyond RAPNO-defined radiographic progression
Many patients continued OJEMDA beyond RAPNO-defined radiographic progression by IRC Updated 3-year analysis In the 3-year follow-up analysis, 38† patients had RAPNO-defined PD while on OJEMDA 100% Proportion of patients with PD while on tovorafenib (%) 75% OJEMDA Reduced tumor size‡ 50% beyond PD: a
Slide 23: RAPNO PFS demonstrates efficacy; time to next treatment reflects full clinical benefit
RAPNO PFS demonstrates efficacy with OJEMDA; time to next treatment more accurately reflects the full clinical benefit Updated 3-year analysis Median time to next treatment§ was 42.6 months (95% CI 36.7–NE) 1.0 • RAPNO defines radiographic PD as a ≥25% increase in tumor size from nadir₸—not baseline
Slide 24: Tumor rebound was minimal in the first months off therapy
Tumor rebound was minimal in the first 6 months off therapy Updated 3-year analysis (! ?6NP4R6TNTMb64.CN:.gChA i4R6TNTMb64.CN:.g%CAM Post-treatment +,-.LMNO.NP4R6TN8O9MN:;MTN<=>?@ANB6R;-TMCNaOP, b-8McO.MN:+%d%ANC4TO.LNP,MN6b8MTe-PO6.N;MTO6CN:IA #! observation patients, n=39 )! 3 months 6 months post
Slide 25: Early evidence of retreatment activity observed in the OJEMDA-retreated cohort
Early evidence of retreatment activity observed in the OJEMDA-retreated cohort Updated 3-year analysis Patients retreated with OJEMDA n=8 At time of data cutoff: -38.3 • All 8 patients receiving OJEMDA Median change, % (range)* (-80.9–0) retreatment were still on therapy • Median tumor size† was sma
Slide 26: 77% of patients were treatment free for at least 12 months
77% of 39 patients were treatment free for at least 12 months; median treatment-free interval not yet reached Updated 3-year analysis 100 90 Post-treatment observation patients n=39† 80 Proportion of patients (%) 70 Median duration of treatment, months (range) 24.6 (16.0–38.7) 60 50 Treatment free M
Slide 27: No new safety signals were observed in the 3-year update
No new safety signals were observed in the 3-year update Updated 3-year analysis Safety analysis set Safety analysis set Preferred term* (n=137) (n=137), n (%) Grade ≥3 TRAEs, n (%) All TEAEs 137 (100) Any 91 (66) All TRAEs 136 (99) Decreased growth velocity 46 (34) Grade ≥3 TEAEs 113 (82) Anemia 19
Slide 28: FIREFLY-2
FIREFLY-2 Pivotal Phase 3 trial of tovorafenib in front-line pLGG Bradon Living with pLGG since age 11 28
Slide 29: FIREFLY-2: 1L pLGG approval represents the largest future growth lever for OJEMDA
FIREFLY-2: 1L pLGG approval represents the largest future growth lever for OJEMDA by doubling the commercial opportunity Estimated Annual Treatment Decisions1 ~1,100 Key Value-Creation Milestones 1L pLGG ~2,200 • FIREFLY-2 enrollment completion Total expected 1H 2026 Treatment Decisions • Topline da
Slide 30: Expansion into front-line treatment represents a meaningful opportunity for tovorafenib
Expansion into front-line treatment represents a meaningful expansion opportunity for tovorafenib in pLGG Trial design Endpoints • Randomized, global, registrational Phase 3 trial of monotherapy tovorafenib • Primary endpoint: ORR based on RAPNO-LGG criteria, assessed by vs SoC chemotherapy blinded
Slide 31: Emi-Le
Emi-Le B7-H4-targeted antibody-drug conjugate (ADC) 31
Slide 32: Emi-Le: Transformational opportunity in Adenoid Cystic Carcinoma (ACC)
Emi-Le: Transformational opportunity in Adenoid Cystic Carcinoma (ACC) High-impact clinical program parallels ~3-year line of sight to OJEMDA’s rapid development and registration potential approval and • Potential first-in-class program targeting subsequent meaningful a defined, treatment-resistant
Slide 33: Emi-Le Program Overview
Emi-Le Program Overview Emi-Le in ACC ACC patient population1,2 Opportunity for Day One • Investigational B7-H4- • Annual U.S. incidence of • Emerging clinical data targeted ADC ~1,300 patients, conducive to rapid including: progression toward • Mechanism and registration modality well matched • ACC
Slide 34: DAY301
DAY301 PTK7-targeted antibody-drug conjugate (ADC) 34
Slide 35: DAY301: Next generation ADC targeting PTK7
DAY301: Next generation ADC targeting PTK7 Potential first-in-class asset Antibody DAY301 Structure • High-affinity PTK7-targeted IgG1 antibody optimized for tumor penetration while limiting off-target exposure1 Payload • High-potency topo-1 payload with enhanced bystander activity2,3 Polysarcosine
Slide 36: PTK7: Well-suited as an ADC target
PTK7: Well-suited as an ADC target Clinically validated ADC target PTK7 overview PTK7 is Broadly Expressed Across Structure: single-pass transmembrane Multiple Solid Tumor Types protein in the pseudokinase family of receptor tyrosine kinases1,2 Expression: overexpressed in a broad range of solid tum
Slide 37: DAY301: Improved tumor regression activity demonstrated vs. benchmarks
DAY301: Improved tumor regression activity demonstrated vs. benchmarks in multiple preclinical models PDX 362797 SCLC PDX 362310 TNBC PDX LD1-200615 HNSCC H-score 210 H-score 255 H-score 120 DAY301 has been designed to maximize therapeutic index to overcome limitations of prior PTK7 programs and sta
Slide 38: DAY301: Initial Phase 1a/b clinical trial design
DAY301: Initial Phase1a/b clinical trial design Phase 1a: Monotherapy Phase 1b: Monotherapy Key Design Elements Dose Escalation1 Dose Expansion and Optimization • BOIN design for efficiency • Simon 2-stage design, initial dose optimization followed by expansion into RD1 and RD2 cohorts of dose escal
Slide 39: Summary
Summary 39
Slide 40: Fourth quarter & full year 2025 financial results
Fourth quarter & full year 2025 financial results Financial Summary Three Months Ended Three Months Ended Full Year Ended Full Year Ended ($ in millions) 12/31/25 12/31/24 12/31/25 12/31/24 OJEMDA Net Revenue 52.8 29.0 155.4 57.2 License Revenue 0.9 0.2 2.8 73.9 Total Revenue $53.7 $29.2 $158.2 $131
Slide 41: Day One poised for a transformational 2026
Day One poised for a transformational 2026 Advancing Pipeline Deliver on 2026 net product revenue Advance Emi-Le: Deliver Phase 1 clinical guidance data by mid-2026, progress to later-stage development Complete FIREFLY-2 trial enrollment in 1H 2026, enabling mid-2027 data readout and Report Phase 1
Slide 42: Appendix
Appendix 42
Slide 43: Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations
Tovorafenib inhibits both BRAF fusions and BRAF V600 mutations MAPK RAS-independent activation of the Tovorafenib is an investigational, oral, pathway MAPK pathway selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF RAS kinase • Activity in tum
Day One Biopharmaceuticals — Q4 2025 Earnings Presentation on 6ix